Business Wire

From Clinical Trial Efficacy to Real-World Effectiveness First AJOVY® ▼ (fremanezumab) Data from European Real World Evidence Program

Share

8 November 2021, Teva Germany (GmbH) presented at the DGN Congress 2021 the first interim analysis results of the FINESSE study aiming to provide real-world evidence of fremanezumab treatment outcomes by evaluating effectiveness in routine clinical practice. 97.6% of patients included in the study had already received preventive migraine therapies in the 10 years prior to study entry, including antidepressants, anticonvulsants, beta-blockers, ca-antagonists, onabotulinumtoxinA as well as other anti-CGRP mAbs.1

The interim analysis results were shared in a poster presentation at the congress by Prof. Andreas Straube, from Ludwig-Maximilians University Munich, Germany, who is the principal investigator of the study.

The presented FINESSE interim data1 indicate that real-world response rates are consistent with Phase-III-study results of fremanezumab.2,3,4 “The results indicate that anti-CGRP mAbs such as fremanezumab also work outside of randomized clinical trials in a migraine patient population who has previously experienced inadequate response to multiple preventive therapies. Real-world evidence can provide vital insight into treatment effects in more naturalistic clinical settings, where many patients have multiple co-morbidities”, said Professor Straube.

The primary endpoint measure was the proportion of patients reaching ≥ 50% reduction in the monthly average number of migraine days evaluated during the 6-month period after the first dose of fremanezumab.

  • 48.7% of the patients with 6-month data achieved the primary endpoint, with a higher percentage in EM (53.2%) than CM patients (43.0%). Real-world response rates are thus in line with Phase-III-study results of fremanezumab.
  • The mean number of migraine days per month (d/m) decreased from 12.7 (baseline) to 6.2 (month 6).
  • From baseline to month 6, the mean MIDAS Score decreased from 74.8 at baseline to 32.8 and the mean HIT-6 Score from 65.9 at baseline to 56.6
  • Acute migraine medication use decreased from 9.6 days/month at baseline to 4.4 d/m at month 6.

Danilo Lembo, Vice President Teva Medical Affairs EU commented:

To provide further support in understanding migraine prevention in clinical practice, we have initiated a comprehensive European Real World Evidence program with FINESSE and PEARL studies which are being carried out throughout Europe.

“Today we are excited to see these first interim results from the FINESSE study which are a strong validation of the data previously seen with Teva’s migraine preventive treatment.

“Real-world evidence (RWE) studies provide information that is relevant to patient care and can help clinicians, researchers, regulators and payers to better understand the drugs and their impact on patients outcomes.

“Also real-world evidence is complementary to randomized clinical trial and in recent years it has become increasingly important to improve clinical practice, amend treatment guidelines and support access decisions.”

About the Study

  • FINESSE is a 49-month (25-month recruitment and 24-month follow-up) multicenter, two-country (Germany/Austria), prospective observational study.
  • Eligible patients are adults (≥ 18 years) diagnosed with EM or CM who have been prescribed fremanezumab according to the Summary of Product Characteristics (SmPC).
  • The primary endpoint is the proportion of patients reaching ≥ 50% reduction in the monthly average number of migraine days evaluated during the 6-month period after the first dose of fremanezumab.
  • Relevant secondary effectiveness endpoints include changes from baseline in: (1) Monthly average number of migraine days; (2) Disability scores; (3) Days of acute migraine medication use per month.
  • Effectiveness data is evaluated using data from patient diaries and patient-reported outcome measures (disability scores).
  • Recruitment of the FINESSE study is still ongoing.

About AJOVY® (fremanezumab-vfrm) injection

AJOVY is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled syringe or a pre-filled pen. Two dosing options are available: 225 mg once monthly administered as one subcutaneous injection (monthly dosing), or 675 mg every three months (quarterly dosing), which is administered as three subcutaneous injections.

AJOVY can be administered either by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment.

Information for Europe about AJOVY® can be found here.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events.

Adverse events should be reported. Reporting forms and information can be found at https://www.hpra.ie.

About Teva

Teva has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

References:

  1. Straube A et al. Effectiveness of Fremanezumab for Preventive Treatment in Migraine: The Non-Interventional FINESSE Study. Poster presented at DGN Congress 2021, November 3-6, 2021
  2. Dodick DW et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine. A Randomized Clinical Trial. JAMA. 2018;319(19):1999–2008. doi:10.1001/jama.2018.4853
  3. Silberstein SD, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017;377:2113–22. doi:10.1056/NEJMoa1709038
  4. Ferrari MD et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019:394(10203):1030–1040. doi:10.1016/S0140-6736(19)31946-4

Safe Harbour Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to the commercial success of AJOVY; our ability to successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, competition for our specialty products, including AUSTEDO®, AJOVY and COPAXONE®; our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional pharmaceutical products, and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness; our business and operations in general, including uncertainty regarding the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general, our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith, costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic; compliance, regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2020, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Fiona Cohen, Teva Corporate Communications Europe : +31 6 2008 2545

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nel ASA: Receives Purchase Order for 20MW Alkaline Electrolyser From Ovako26.11.2021 22:45:00 EET | Press release

Nel Hydrogen Electrolyser AS, a division of Nel ASA (Nel, OSE:NEL), has received a purchase order for a 20MW alkaline water electrolyser from Ovako, a leading European manufacturer of engineering steel. The electrolyser will be installed at Ovako’s existing plant in Hofors, Sweden. The fossil-free hydrogen will replace the use of fossil propane gas currently used in the heating furnaces. “We are excited to announce the delivery of electrolyser equipment to Ovako. There is huge potential in reducing CO2-emissions from steel-heating processes through green hydrogen. We look forward to working with Ovako and its partners to further develop fossil-free steel production,” says Jon André Løkke, CEO at Nel. The purchase order has a contract value of approximately EUR 11 million with equipment delivery in late 2022. The electrolyser will produce oxygen and hydrogen for Ovako’s steel-heating process and is a major step towards zero-carbon emission steel production. The conversion to hydrogen wi

'Afghan Girl' Sharbat Gula Safely Evacuated to Italy Via Efforts of Photographer Steve McCurry, Metagood/OnChainMonkey Crypto Community & Future Brilliance Charity26.11.2021 20:16:00 EET | Press release

The legendary 'Afghan Girl' photographer, Steve McCurry, and his sister, Bonnie McCurry, are delighted to announce that, together with the British-American charity, Future Brilliance, and with the support of the Italian government, and NFT for Social Good platform Metagood, they have been able to bring the famous icon for Afghan female refugees, Sharbat Gula, to safety. Background: Six weeks ago, Bonnie McCurry reached out to Future Brilliance founder, impact pioneer, and investor Sophia Swire who has a 30-year track record of empowering women in Afghanistan. She told Sophia that Sharbat Gula wanted to be evacuated with her family. After considering all the various country options, they confirmed with Sharbat that her family hoped to seek asylum in Italy. Sophia and her team activated the Future Brilliance network in Afghanistan and, together with the McCurry family, arranged the necessary paperwork, visas, and logistics. The NFT for good platform Metagood (who worked with McCurry to d

ZOVOO Held Distributor Conference, Creating a Splash of Colour in Atomization Industry26.11.2021 18:45:00 EET | Press release

At 9:30pm (GMT +8) on November 12, ZOVOO, a new industry-leading atomization company, held its 2021 distributor conference online. Distributors from United States, United Kingdom, France and other countries participated in the conference. Meanwhile, ZOVOO also displayed its newly developed disposable products DRAGBAR series for the first time to the public, which attracted widespread attention from distributors worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211126005521/en/ (Photo: Business Wire) Founded in 2010, ZOVOO has sophisticated research and develop capability, forward-looking product design and perfect supply chain system. ZOVOO founding team has 10 years of proven strength and experience. They have the absolute advantages in terms of heating materials, air channel structure design, etc., and build up the five criteria of good flavor. The birth of each product needs to go through from R&D, design, product

Indeed and Quandoo Announce Partnership to Support the Restaurant Industry Hiring Crisis26.11.2021 17:21:00 EET | Press release

Indeed, the world’s largest jobs site, and Quandoo, one of the fastest growing restaurant reservation platforms worldwide, today announce a partnership to support the restaurant industry's current hiring crisis. This partnership will see restaurants be provided with £50 credit to post a sponsored job advertisement on Indeed’s platform. Sponsored jobs advertisements receive optimal visibility and are more likely to deliver hires* which Indeed and Quandoo hope will connect staff with the restaurants that need them the most. Employers posting a job on Indeed for the first time will have £50 credited to their account to start sponsoring their jobs and reaching more candidates. Employers in the UK can claim the offer here . “We are so excited about this partnership. It’s a topic that is close to home for us at Quandoo as we are hearing how challenging it is to find staff from our partners. So we wanted to do our bit to support the wider industry in any way we can. By partnering with Indeed

The Leading Event for Payment, Identification and Security Professionals, TRUSTECH will present all the Latest trends in the sector26.11.2021 12:34:00 EET | Press release

For three days, professionals of the cards and digital trust technologies industries will meet at the TRUSTECH exhibition in Paris to discuss the issues and challenges of identity, security and payment, which are the real pillars of the digital transition for institutional or commercial organisations. A panel of international speakers will share their insights across the multiple conference sessions The 6,000 attendees expected from all over the world will also be able to discover concrete solutions to optimise their business and develop their practices. Visitors will have FREE access to participate at Trustech conferences program. AUTHENTICATION AND IDENTIFICATION: A STRATEGIC ISSUE FOR GOVERNMENTS AND ORGANISATIONS These new demands on governments require the use of increasingly complex technologies and processes. Digitization brings into question how the use of physical official documents will be used in the future. It also implies there will be new innovations regarding how physica

Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis26.11.2021 09:00:00 EET | Press release

Already for the seventh consecutive year of Iron Deficiency Day, Vifor Pharma is supporting a growing international alliance including the Heart Failure Policy Network, European Kidney Health Alliance, Global Heart Hub and Croí the West of Ireland Cardiac Foundation with the aim to educate people about the importance of iron for the body and what can happen if iron levels are not properly managed. Iron Deficiency Day 2021 encourages people at risk to listen to their body, to take iron seriously and to take control over their health by seeking early diagnosis and medical help from their physician. Iron Deficiency affects about half of the patients with chronic kidney disease2 and chronic heart failure and is associated with reduced quality of life3, an increased risk of hospitalization4 and cardiovascular death5. Despite the serious consequences and high prevalence, of iron deficiency, the condition remains under-recognized6. Diagnosis and treatment of iron deficiency has been further i

LightCON Unveils Global Teaser Site for New Mobile Game 'Rise of Stars (ROS)'26.11.2021 05:00:00 EET | Press release

Rise of Stars (ROS), a new mobile game that is being developed by LightCON, a subsidiary of WEMADE MAX (Co-CEOs: Hyunguk Chang, Gilhyung Lee) (KOSDAQ: 101730), today opened its global teaser site. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211125006252/en/ LightCON unveils global teaser site for new mobile game 'Rise of Stars (ROS).' ROS is a new mobile SF strategy game featuring elaborately designed warships and planets set in the vast universe. Under the slogan, 'The 4x Blockchain Game for the Greatest Conqueror,' the teaser site was designed to help users experience the unique atmosphere of ROS and the game concept with the representative image of the game. ROS will be building a system for players to obtain game tokens through resource mining within planets. It aims for a global launch in the 1st quarter of 2022. (Graphic: Business Wire) Under the slogan, ‘The 4x Blockchain Game for the Greatest Conqueror,’ the tease

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom